Vaginal Suppository Dual-Phase Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaginal suppositories with imidazole antifungal active ingredients face challenges in maintaining effective concentration and adhesion to vaginal mucosal surfaces, leading to high recurrence rates of fungal infections due to poor solubility and rapid dissolution of active ingredients, necessitating frequent administration and incomplete coverage of the vaginal area.
Innovation Solution
A vaginal suppository formulation containing a combination of dissolved and suspended antifungal active ingredients in a polyethylene-glycol and polysorbate base, where the ratio of both forms is reproducible and stable, allowing for deeper penetration and prolonged release of the active ingredient, ensuring effective coverage of the vaginal mucosal membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the active ingredient is used in high doses to achieve sufficient blood concentration for treating fungal infections, then the therapeutic effect is improved, but the formulation difficulty increases and undesired side effects occur
Solution Approach 1:
The patent uses vaginal suppositories as an intermediary delivery system to provide local treatment of fungal infections. The suppository base (polyethylene-glycol with polysorbate) acts as a mediator that releases the active ingredient directly at the infection site, avoiding the need for high systemic doses and their associated side effects. This local delivery mechanism achieves therapeutic effect while minimizing harmful effects.
2Stability of the object's composition
If the active ingredient is formulated in suspended form in oleaginous base to improve adhesion, then the adhesion to mucosal surface is improved, but the penetration into narrow folds of mucosal membrane is reduced
Solution Approach 1:
The patent changes the physical parameters of the suppository base by using polyethylene-glycol instead of traditional oleaginous bases. This parameter change provides both adequate adhesion and the ability to penetrate into narrow folds of the vaginal mucosa, achieving both requirements simultaneously through modification of the base material properties.
Solution Approach 2:
The patent creates a composite suppository base combining polyethylene-glycol and polysorbate. This composite material integrates the adhesive properties needed for retention with the penetration capability required to reach into narrow mucosal folds, resolving the contradiction between adhesion and coverage area.
3Speed
If the active ingredient is dissolved in the suppository base for rapid effect, then the onset of action is improved, but the duration of action is reduced due to rapid dissolution
Solution Approach 1:
The patent segments the active ingredient into two distinct forms within the suppository: dissolved and suspended portions. The dissolved fraction provides rapid onset of action by immediately available active ingredient, while the suspended fraction ensures prolonged duration by gradually releasing active ingredient over time. This segmentation resolves the contradiction between speed and duration of action.
Solution Approach 2:
The patent achieves continuous therapeutic action by combining dissolved and suspended forms of the active ingredient. The dissolved portion provides immediate effect while the suspended portion continuously releases active ingredient, ensuring uninterrupted therapeutic coverage throughout the treatment period.
4Duration of action of moving object
If the suppository base is designed for sustained release to extend duration of action, then the duration is improved, but the penetration into narrow folds of mucosal membrane is reduced
Solution Approach 1:
The patent modifies the physical parameters of the sustained-release mechanism by using polyethylene-glycol base with specific viscosity and adhesion properties. This parameter change allows the sustained-release formulation to simultaneously penetrate into narrow vaginal folds while maintaining prolonged duration of action, overcoming the limitation of traditional sustained-release systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual-formulation suppository achieves enhanced therapeutic efficacy by rapid penetration and prolonged release of the active ingredient, reducing recurrence rates and improving patient convenience by maintaining effective concentrations for an extended period without the need for frequent administration.
Implementation Method 1
a vaginal suppository with improved efficacy containing an antifungal active ingredient, wherein said active ingredient is present simultaneously in dissolved and suspended form in a suppository base containing polyethylene-glycol and polysorbate
Implementation Method 2
said active ingredient is present simultaneously in dissolved and suspended form
Implementation Method 3
deeper penetration and prolonged release of the active ingredient, ensuring effective coverage of the vaginal mucosal membrane
Implementation Method 4
prolonged release of the active ingredient, reducing recurrence rates and improving patient convenience by maintaining effective concentrations for an extended period
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The subject of the invention is a vaginal suppository with improved efficacy containing an antifungal active ingredient, wherein the said active ingredient is present simultaneously in dissolved and suspended form in the suppository base containing polyethylene-glycol and polysorbate. The ratio of the suspended and dissolved active ingredient in the suppository is reproducible and said ratio does not change during the storage. A further subject of the present invention is a process for manufacturing said pharmaceutical formulations.